The Role of Lactate Dehydrogenase in Exploring the Immune Evasion in HCC Patients Who Underwent TACE: Implications for Clinical Application.

Yang Xie, Xiangyang Sun, Fubo Xie, Wencheng Jian, Qingliang Wang, Xiaochen Ma, Caixia Li, Kai Zhang
Author Information
  1. Yang Xie: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China. ORCID
  2. Xiangyang Sun: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  3. Fubo Xie: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  4. Wencheng Jian: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  5. Qingliang Wang: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  6. Xiaochen Ma: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  7. Caixia Li: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
  8. Kai Zhang: Department of Radiology, Qilu Hospital of Shandong University, Shandong, People's Republic of China. ORCID

Abstract

Purpose: To examine the relationship between lactate dehydrogenase (LDH) levels and soluble programmed cell death-ligand 1 (sPD-L1) levels in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
Methods: A total of 83 hCC patients participated in this study. Patients were categorized into subgroups based on their alpha-fetoprotein (AFP) levels, presence or absence of extrahepatic metastasis, vascular invasion, Barcelona Clinic Liver Cancer (BCLC) stage, tumor response, tumor size, and number LDH and sPD-L1 levels were compared before and after TACE (3, 7, and 30 days post-TACE).
Results: LDH and sPD-L1 levels were significantly higher at 3 and 7 days post-TACE than at baseline. Positive correlations were observed between changes in LDH levels and sPD-L1 levels at 3 and 7 days post-TACE. LDH levels were higher in patients with elevated AFP compared to those in the normal AFP group at 3 and 7 days post-TACE, in the stable disease (SD) group compared to complete response (CR) and partial response (PR) groups at 7 days post-TACE, and in those with tumor > 5 cm compared with those with tumor ��� 5 cm at 3 and 7 days after TACE (all < 0.05). sPD-L1 levels were higher in patients with vascular invasion than those without vascular invasion at 3 and 7 days post-TACE, in the SD group compared to CR and PR groups at 3 and 7 days post-TACE, and in those with tumor > 5 cm compared to those with tumor < 5 cm at 3 and 7 days after TACE (all < 0.05).
Conclusion: A positive correlation was found between LDH expression and sPD-L1 levels, suggesting LDH as a potential biomarker for assessing immune status in HCC patients following TACE.

Keywords

References

  1. Asia Pac J Clin Oncol. 2022 Oct;18(5):e515-e523 [PMID: 35289092]
  2. Adv Exp Med Biol. 2020;1248:33-59 [PMID: 32185706]
  3. Infect Agent Cancer. 2022 Jun 16;17(1):31 [PMID: 35710505]
  4. Biomed Res Int. 2016;2016:7196280 [PMID: 27314036]
  5. Mol Med Rep. 2015 Oct;12(4):6065-71 [PMID: 26239573]
  6. Cancer Res. 1964 Apr;24:389-99 [PMID: 14147812]
  7. Histopathology. 2021 Jul;79(1):36-46 [PMID: 33326644]
  8. Cancer Immunol Immunother. 2018 Sep;67(9):1331-1348 [PMID: 29974196]
  9. J Hepatol. 2018 Jul;69(1):182-236 [PMID: 29628281]
  10. BMC Cancer. 2014 Feb 20;14:110 [PMID: 24552144]
  11. Front Immunol. 2022 Apr 13;13:869993 [PMID: 35493518]
  12. J Immunother Cancer. 2021 Sep;9(9): [PMID: 34593621]
  13. Acta Oncol. 1997;36(2):183-9 [PMID: 9140436]
  14. Cancers (Basel). 2019 Jul 30;11(8): [PMID: 31366113]
  15. Hepatology. 2016 Dec;64(6):2038-2046 [PMID: 27359084]
  16. Immunity. 2018 Mar 20;48(3):434-452 [PMID: 29562194]
  17. J Surg Oncol. 1973;5(3):251-7 [PMID: 4712290]
  18. Ann Oncol. 2016 Aug;27(8):1492-504 [PMID: 27207108]
  19. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  20. Pathol Oncol Res. 2020 Apr;26(2):735-742 [PMID: 30767115]
  21. Front Immunol. 2022 Mar 01;13:848387 [PMID: 35300325]
  22. J Hepatol. 2019 May;70(5):999-1007 [PMID: 30738077]
  23. J Crit Care. 2017 Oct;41:161-165 [PMID: 28554094]
  24. Clin Cancer Res. 2011 Oct 1;17(19):6250-6261 [PMID: 21844011]
  25. Cancer Res. 2017 Jul 1;77(13):3632-3643 [PMID: 28446465]
  26. Mol Cancer. 2022 Jan 21;21(1):28 [PMID: 35062949]
  27. Int J Surg. 2018 Apr;52:297-302 [PMID: 29530828]
  28. Eur Radiol. 2022 Apr;32(4):2437-2447 [PMID: 34718844]
  29. PLoS One. 2012;7(3):e32653 [PMID: 22461886]
  30. Science. 1963 Jun 21;140(3573):1329-30 [PMID: 17802174]
  31. Prog Transplant. 2017 Mar;27(1):53-57 [PMID: 27555073]

Word Cloud

Created with Highcharts 10.0.0levels7days3LDHpost-TACEsPD-L1tumorcomparedpatientsTACE5cmHCCAFPvascularinvasionresponsehighergroup<lactatedehydrogenasesolubleprogrammedcellhepatocellularcarcinomatransarterialchemoembolizationPatientsSDCRPRgroups>005Purpose:examinerelationshipdeath-ligand1undergoingMethods:total83 hCCparticipatedstudycategorizedsubgroupsbasedalpha-fetoproteinpresenceabsenceextrahepaticmetastasisBarcelonaClinicLiverCancerBCLCstagesizenumber30Results:significantlybaselinePositivecorrelationsobservedchangeselevatednormalstablediseasecompletepartial���withoutConclusion:positivecorrelationfoundexpressionsuggestingpotentialbiomarkerassessingimmunestatusfollowingRoleLactateDehydrogenaseExploringImmuneEvasionUnderwentTACE:ImplicationsClinicalApplicationimmunotherapydeathligand-1

Similar Articles

Cited By

No available data.